Table 2 Overview of diagnostic panel sera assessed for the presence of VACV-reactive or MPXV-reactive antibodies by ELISA and MVA-neutralizing or MPXV-neutralizing antibodies by PRNT
Before 1974 and PCR− | Before 1974 and PCR+ | After 1974 and PCR− | After 1974 and PCR+ | ||
|---|---|---|---|---|---|
VACV ELISA | |||||
Sera | 19 | 13 | 21 | 19 | |
Responder | 10 | 10 | 0 | 5 | |
Percentage (%) | 53 | 77 | 0 | 26 | |
GMT | 43 | 846 | 10 | 24 | |
MPXV ELISA | |||||
Sera | 11 | 12 | 5 | 7 | |
Responder | 1 | 8 | 0 | 0 | |
Percentage (%) | 9 | 67 | 0 | 0 | |
GMT | 10 | 123 | 10 | 10 | |
MVA PRNT | |||||
Sera | 11 | 12 | 5 | 7 | |
Responder | 0 | 5 | 0 | 0 | |
Percentage (%) | 0 | 42 | 0 | 0 | |
GMT | 10 | 41 | 10 | 10 | |
MPXV PRNT | |||||
Sera | 11 | 12 | 5 | 7 | |
Responder | 7 | 10 | 0 | 5 | |
Percentage (%) | 64 | 83 | 0 | 71 | |
GMT | 41 | 185 | 10 | 176 | |
Total | |||||
Sex (M/F)a | 14/5 | 12/1 | 17/4 | 19/0 | |
Age (years)b | 57 (range, 51–80) | 57 (range, 52–65) | 29 (range, 20–42) | 35 (range, 21–41) | |
